<p>雅培（Abbott Laboratories，股票代碼：ABT）週一宣佈，加拿大衞生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。</p>
<p>該設備用於治療下肢慢性威脅性缺血（CLTI）患者。它可以保持動脈通暢，並釋放藥物依維莫司，以支持在支架完全溶解之前的癒合。</p>
<p>超過 80 萬加拿大人患有周圍動脈疾病（PAD）。CLTI 是 PAD 的一種嚴重形式，動脈因斑塊堵塞而阻礙血液和氧氣流向小腿和腳部。CLTI 患者常常經歷劇烈疼痛和難以癒合的開放性傷口。</p>
<p>如需評論和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

雅培

<p>雅培已獲得加拿大衞生部批准其 Esprit BTK 依維莫司釋放可吸收支架系統，該可溶支架旨在治療膝下慢性肢體威脅缺血（CLTI）。該設備有助於保持動脈通暢，並釋放藥物依維莫司以促進癒合，直至其完全溶解，滿足超過 80 萬名患有外周動脈疾病（PAD）的加拿大人的需求</p>

<p>Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories，股票代碼：ABT）週一宣佈，加拿大衞生部已批准其可溶解支架——Esprit BTK Everolimus Eluting Resorbable Scaffold System。</p>
</div><p>The device is used to treat people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). It keeps arteries open and delivers the drug everolimus to support healing before the stent fully dissolves.</p>
<div class="lb-trans"><p>該設備用於治療下肢慢性威脅性缺血（CLTI）患者。它可以保持動脈通暢，並釋放藥物依維莫司，以支持在支架完全溶解之前的癒合。</p>
</div><p>More than 800,000 Canadians are living with Peripheral Artery Disease (PAD). CLTI is a severe form of PAD in which arteries become clogged with plaque, blocking blood flow and oxygen to the lower leg and foot. People with CLTI often experience severe pain and non-healing open wounds.</p>
<div class="lb-trans"><p>超過 80 萬加拿大人患有周圍動脈疾病（PAD）。CLTI 是 PAD 的一種嚴重形式，動脈因斑塊堵塞而阻礙血液和氧氣流向小腿和腳部。CLTI 患者常常經歷劇烈疼痛和難以癒合的開放性傷口。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需評論和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

雅培的 Esprit BTK 可溶解支架已獲加拿大衞生部批准